O. A. Rachinskaya

O. A. Rachinskaya

Auto-generated profile, based on publicly available information

O. A. Rachinskaya

Scientific Centre for Expert Evaluation of Medicinal Products

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2011 in Russian Journal of Genetics
Verified
Journal Article
Closed access
PDF file
ORO. A. Rachinskaya
O. A. Rachinskaya
VLV. A. Lemesh
V. A. Lemesh
OMOlga Muravenko
Olga Muravenko
OYOlga Yu. Yurkevich
Olga Yu. Yurkevich
EGE. V. Guzenko
E. V. Guzenko
AZA. V. Zelenin
A. V. Zelenin
Using a set of approaches based on the use of molecular cytogenetic markers (DAPI/C-banding, estimation of the total area of DAPI-positive regions in prophase nuclei, FISH with 26S and 5S rDNA probes)

28 September 2018 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ЕМЕ. В. Мельникова
Е. В. Мельникова
AGA. A. Goryaev
A. A. Goryaev
MSM. V. Savkina
M. V. Savkina
OMO. V. Merkulova
O. V. Merkulova
ACAlexander Chaplenko
Alexander Chaplenko
VMV. A. Merkulov
V. A. Merkulov
The intensive development of cellular technologies stipulates the introduction at the global level of medicinal products based on viable human cells, which in most countries are referred to as biomedical cell products. The authors conducted a comparative analysis of the regulatory framework in different countries and determined special aspects of regulation of cell therapy products (analogues of biomedical cell products). Some countries have mechanisms for priority review of cell therapy products for marketing authorization, such as accelerated assessment, accelerated approval, or conditional marketing authorisation. These mechanisms are currently absent in Russia, because of the novelty of the regulatory framework, and the biological properties of innovative cell products. Biomedical cell products are regarded as a separate class of medicinal products in Russia, they are not treated as biologicals and are regulated by the Federal Law No. 180-FZ «On Biomedical Cell Products» of June 23, 2016. The main difference in regulation of cell-based products in the Russian Federation is the principle of unified requirements for marketing authorisation of autologous, allogeneic, and combined biomedical cellular products, and the absence of the «hospital exemptions» mechanism that exists in many countries. This mechanism allows prescription and use of personalised autologous medicines produced in the laboratory of a medical institution for a particular patient.

25 March 2019 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ЕМЕ. В. Мельникова
Е. В. Мельникова
ORO. A. Rachinskaya
O. A. Rachinskaya
GTGeorge Trusov
George Trusov
MKM. D. Khorolsky
M. D. Khorolsky
ISI. S. Semenova
I. S. Semenova
VMV. A. Merkulov
V. A. Merkulov
The manufacturer (developer) has to prepare a specification for each newly developed biomedical cell product (BCP) that has passed the stage of preclinical studies. The specification is included into the registration dossier when applying for marketing authorisation of a BCP. In accordance with the Order of the Ministry of Health of the Russian Federation No. 14n of 19 January 2017 «On approval of the specification format for a biomedical cell product» the specification should contain information about authenticity of the cell line used in the BCP, namely: morphological characteristics, expression of specific markers, expression of specific genes, expression of specific proteins, as well as markers of cell line stability. At present Russia has no practical experience in BCP quality evaluation. The aim of the study was to substantiate methodological approaches to authentication of cell lines used in BCPs as illustrated by quality evaluation of the DF-2 model cell line using test methods that allow for characterisation of the morphological, genetic, immunophenotypic, and cytogenetic profile of the cell line. Materials and methods: the study analysed the DF-2 cell line — human dermal fibroblasts (mesenchymal stem cells) obtained from the Institute of Cytology of the Russian Academy of Sciences (St. Petersburg). The following analytical test methods were used in the study: morphological analysis; flow cytometry for immunophenotyping of the DF-2 model cell line; short tandem repeats for creating an allelic profile of the model cell line; cytogenetic analysis — differential DAPI staining of metaphase chromosomes. Results: the paper summarises methodological approaches to identification testing of medicines containing living human cells (BCP analogues) currently used in international practice, and presents the results of authentication of the model cell line. Conclusions: methods used for BCP identification testing should ensure unambiguous authentication of the cell line according to its specification. The study performed helped to work out the procedure of authentication of a model cell line.

2 October 2021 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
ЕМЕ. В. Мельникова
Е. В. Мельникова
ORO. A. Rachinskaya
O. A. Rachinskaya
VMV. A. Merkulov
V. A. Merkulov
One of the promising areas in the development of innovative products for the treatment of cancer is the use of oncolytic (native or genetically modified) viruses (OLVs) for selective targeting of tumour cells and their destruction, especially as part of combination therapy. At present, there are three OLV-based products approved for medical use (two in China and one in the USА and EU). The aim of the study was to analyse data on specific aspects of OLV-based products’ development, preclinical and clinical research, and authorisation process in China. The authors analysed data freely available on the manufacturers’ websites, in public reports and documents of the Chinese regulatory authorities, in international clinical trial registries, and scientific publications. The products Gendicine® (SiBiono GeneTech Co., Ltd.) and Oncorine® (Shanghai Sunway Biotech Co., Ltd.) were originally developed and approved in China for clinical use as part of combination therapy. The analysis demonstrated long product development periods (Gendicine had been studied for 14 years before the start of the authorisation procedures), complex preclinical trial designs, and potential use of the products for several medical conditions with different tumour localisation. The identified specific aspects of OVL-based products’ development and authorisation in China could be taken into account in the regulatory practice of the Russian Federation.

11 December 2019 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ORO. A. Rachinskaya
O. A. Rachinskaya
MVM. A. Vodyakova
M. A. Vodyakova
ЕМЕ. В. Мельникова
Е. В. Мельникова
VMV. A. Merkulov
V. A. Merkulov
Genetic diseases are often progressive in nature, and without proper treatment may result in disability or death. Difficulties with diagnosis of genetic diseases and lack of effective treatment are global public health challenges. Medical care for patients with genetic diseases is often confined to symptomatic and palliative care. Starting from the 2000s, great hopes have been placed on cell-based medicinal products (which are referred to as biomedical cell products in the Russian legislation) and gene therapy products. The aim of the study was to review current trends in the development of biomedical cell products for the treatment of genetic diseases. The paper focuses on cell-based products for the treatment of monogenic genetic diseases, such as severe combined immunodeficiency (SCID), recessive dystrophic epidermolysis bullosa (RDEB), beta-haemoglobinopathies, alpha-1-antitrypsin deficiency, haemophilia A, and Duchenne muscular dystrophy. Such drugs are being developed in many countries and are now entering preclinical and different stages of clinical trials. Products based on various types of viable cells, including differentiated cells, stem cells, induced pluripotent cells, as well as cells genetically modified ex vivo, may be developed for the treatment of one and the same disease. The main priority is the creation of such products that will obviate the need for replacement therapy or palliative care, and that will significantly increase life expectancy and quality of life.

29 November 2025 in Innovative Medicine of Kuban
Verified
Journal Article
Open access
PDF file
ORO. A. Rachinskaya
O. A. Rachinskaya
ЕМЕ. В. Мельникова
Е. В. Мельникова
VMV. A. Merkulov
V. A. Merkulov
Особенности дизайна доклинических исследований препаратов генной терапии in vivo. Часть 1: фармакологические исследования